Page 174 - 2018_10-Haematologica-web

X. Wang et al.
Endothelial dysfunction after hematopoietic
stem cell transplantation: role of the condi- tioning regimen and the type of transplanta- tion. Biol Blood Marrow Transplant. 2010;16(7):985-993.
5. Vion AC, Rautou PE, Durand F, et al. Interplay of inflammation and endothelial dysfunction in bone marrow transplanta- tion: focus on hepatic veno-occlusive dis- ease. Semin Thromb Hemost. 2015; 41(6):629-643.
6. Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complica- tions of hematopoietic SCT. Bone Marrow Transplant. 2011;46(12):1495-1502.
7. Tuncer HH, Rana N, Milani C, et al. Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. World J Gastroenterol. 2012;18(16):1851- 1860.
8. Bearman SI, Lee JL, Baron AE, et al. Treatment of hepatic venocclusive disease with recombinant human tissue plasmino- gen activator and heparin in 42 marrow transplant patients. Blood. 1997;89(5):1501- 1506.
9. Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre- emptive antithrombin III replacement and combined antithrombin III/defibrotide ther- apy. Haematologica. 2006;91(6):795-800.
10. Bearman SI, Shen DD, Hinds MS, et al. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol. 1993;84(4):724-730.
11. Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombo- modulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982;257(14):7944-7947.
12. O'Brien LM, Mastri M, Fay PJ. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood. 2000; 95(5):1714-1720.
13. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269(50):31869-31880.
14. Dahlback B, Villoutreix BO. The anticoagu- lant protein C pathway. FEBS Lett. 2005; 579(15):3310-3316.
15. Schuepbach RA, Madon J, Ender M, et al. Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects. J Thromb Haemost. 2012;10(8):1675-1684.
16. Ikezoe T, Takeuchi A, Taniguchi A, et al. Recombinant human soluble thrombomod- ulin counteracts capillary leakage associated with engraftment syndrome. Bone Marrow Transplant. 2011;46(4):616-618.
17. Ikezoe T, Togitani K, Komatsu N, et al.
Successful treatment of sinusoidal obstruc- tive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant. 2010;45(4):783-785.
18. Nakamura D, Yoshimitsu M, Kawada H, et al. Recombinant human soluble thrombo- modulin for the treatment of hepatic sinu- soidal obstructive syndrome post allogeneic hematopoietic SCT. Bone Marrow Transplant. 2012;47(3):463-464.
19. Ohwada C, Takeuchi M, Kawaguchi T, et al. Successful treatment with recombinant sol- uble thrombomodulin of two cases of sinu- soidal obstructive syndrome/hepatic veno- occlusive disease after bone marrow trans- plantation. Am J Hematol. 2011; 86(10):886- 888.
20. Yamamoto S, Yagawa A, Toyama D, et al. Successful treatment of hepatic sinusoidal obstructive syndrome after hematopoietic stem cell transplantation in a child using recombinant thrombomodulin. Acta Haematol. 2013;129(1):62-64.
21. Fujiwara H, Maeda Y, Sando Y, et al. Treatment of thrombotic microangiopathy after hematopoietic stem cell transplanta- tion with recombinant human soluble thrombomodulin. Transfusion. 2016;56(4): 886-892.
22. Ikezoe T, Yang J, Nishioka C, et al. Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cyto- toxicity by upregulation of extracellular sig- nal-regulated kinase/myeloid leukemia cell- 1 signaling. Arterioscler Thromb Vasc Biol. 2012;32(9):2259-2270.
23. Ikezoe T, Yang J, Nishioka C, et al. Thrombomodulin blocks calcineurin inhibitor-induced vascular permeability via inhibition of Src/VE-cadherin axis. Bone Marrow Transplant. 2017;52(2):245-251.
24. Ikezoe T, Yang J, Nishioka C, et al. The fifth epidermal growth factor-like region of thrombomodulin exerts cytoprotective function and prevents SOS in a murine model. Bone Marrow Transplant. 2017;52(1):73-79.
25. Pan B, Wang X, Nishioka C, et al. G-protein coupled receptor 15 mediates angiogenesis and cytoprotective function of thrombo- modulin. Sci Rep. 2017;7(1):692.
26. Pan B, Wang X, Kojima S, et al. The fifth epi- dermal growth factor like region of throm- bomodulin alleviates LPS-induced sepsis through interacting with GPR15. Thromb Haemost. 2017;117(3):570-579.
27. Sampoli Benitez BA, Hunter MJ, Meininger DP, et al. Structure of the fifth EGF-like domain of thrombomodulin: An EGF-like domain with a novel disulfide-bonding pat- tern. J Mol Biol. 1997;273(4):913-926.
28. Kobayashi M, Inoue K, Warabi E, et al. A simple method of isolating mouse aortic
endothelial cells. J Atheroscler Thromb.
2005;12(3):138-142.
29. Qiao J, Fu J, Fang T, et al. Evaluation of the
effects of preconditioning regimens on hepatic veno-occlusive disease in mice after hematopoietic stem cell transplantation. Exp Mol Pathol. 2015;98(1):73-78.
30. DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology. 1999;29(6):1779-1791.
31. Zeng L, An L, Fang T, et al. A murine model of hepatic veno-occlusive disease induced by allogeneic hematopoietic stem cell trans- plantation. Cell Biochem Biophys. 2013;67(3):939-948.
32. Stearns DJ, Kurosawa S, Esmon CT. Microthrombomodulin. Residues 310-486 from the epidermal growth factor precursor homology domain of thrombomodulin will accelerate protein C activation. J Biol Chem. 1989;264(6):3352-3356.
33. Tejero R, Bassolino-Klimas D, Bruccoleri RE, et al. Simulated annealing with restrained molecular dynamics using CONGEN: ener- gy refinement of the NMR solution struc- tures of epidermal and type-alpha trans- forming growth factors. Protein Sci. 1996;5(4):578-592.
34. Lahl K, Sweere J, Pan J, et al. Orphan chemoattractant receptor GPR15 mediates dendritic epidermal T-cell recruitment to the skin. Eur J Immunol. 2014;44(9):2577- 2581.
35. Nguyen LP, Pan J, Dinh TT, et al. Role and species-specific expression of colon T cell homing receptor GPR15 in colitis. Nat Immunol. 2015;16(2):207-213.
36. Kim SV, Xiang WV, Kwak C, et al. GPR15- mediated homing controls immune home- ostasis in the large intestine mucosa. Science. 2013;340(6139):1456-1459.
37. Pan B, Wang X, Kojima S, et al. The fifth epidermal growth factor-like region of thrombomodulin alleviates murine graft- versus-host disease in a G-protein coupled receptor 15 dependent manner. Biol Blood Marrow Transplant. 2017; 23(5):746-756.
38. el Mouelhi M, Kauffman FC. Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver. Hepatology. 1986;6(3):450-456.
39. Park YD, Yasui M, Yoshimoto T, et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant. 1997;19(9):915-920.
40. Salat C, Holler E, Kolb HJ, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubine- mia after bone marrow transplantation. Blood. 1997;89(6):2184-2188.
1740
haematologica | 2018; 103(10)